about
sameAs
Making better influenza virus vaccines?Pseudovirions as vehicles for the delivery of siRNADeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadTargeted vaccine selection in influenza vaccinationInduction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activityProtection of young children from influenza through universal vaccination.Influenza virosomes supplemented with GPI-0100 adjuvant: a potent vaccine formulation for antigen dose sparing.Development of stable influenza vaccine powder formulations: challenges and possibilitiesImmunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients.Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen.Development of a vaccine against pandemic influenza viruses: current status and perspectives.Vaccines for an influenza pandemic: scientific and political challenges.MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxisNasal vaccine innovation.Inactivated influenza vaccines: recent progress and implications for the elderly.Immunobiology of influenza vaccinesVaccines against human diarrheal pathogens: current status and perspectivesEvaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.Full inactivation of human influenza virus by high hydrostatic pressure preserves virus structure and membrane fusion while conferring protection to mice against infection.An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccinesDesign considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensImmunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Novel antigen delivery systems.Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.Pneumonia immunization in older adults: review of vaccine effectiveness and strategiesInfluenza and the challenge for immunology.Lipidomics of host-pathogen interactions.Immunodominance in CD4 T-cell responses: implications for immune responses to influenza virus and for vaccine design.Reconstruction of H3N2 influenza virus based virosome in-vitro.Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations.Immunosupportive therapies in aging.Influenza: the virus and prophylaxis with inactivated influenza vaccine in "at risk" groups, including COPD patientsInfluenza virus-like particle vaccines.Prevention of infectious diseases in older adults through immunization: the challenge of the senescent immune response.Influenza vaccination in the elderly: seeking new correlates of protection and improved vaccines.The virosomal adjuvanted influenza vaccine.MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.T cell responses to viral infections - opportunities for Peptide vaccination.Biomimetic nanoparticles: preparation, characterization and biomedical applications.Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens.
P2860
Q22305647-D160E8B1-E4C7-4072-A80A-231C46839CC7Q24634231-70EAB726-209E-4410-A792-128AE7C8F916Q26783897-8CBBE2A8-EEF0-477B-B9EB-4A3BE472B0D0Q27030899-02E8C009-B964-4EAD-8728-8BD6A0D5E8A3Q27309214-3404FA97-D193-48D9-B098-2F8872E92F33Q27693242-B6947AAB-C403-43FA-A337-73A01C2C29E5Q30353863-F8CA23C6-2B5C-4863-886A-268E7B8A3746Q30368221-598D8B14-C6F5-417C-8115-2F307A709FD0Q30373149-DCBB8F47-624A-4701-9C80-3C691C3AAA43Q30373251-EDC6F82A-0E55-494F-8EBA-933A289BB7FFQ30373784-E43968C0-1C4F-4857-ADBF-FE071EB24B22Q30376971-ED8D61FF-8A0D-4451-B661-CF3E6A2ADEBAQ30377215-58FD8191-7099-4D99-AF2D-61147CDB192AQ30395810-4BF18E05-C5A3-469C-8895-8C4F82E7455AQ30399057-32E16219-14A5-4CF5-8265-463C9BCD7952Q30426771-5E2899C2-91A9-4454-B00F-2F867A0215F3Q33578045-1C2F142A-00AA-4021-AC95-C27A8C2D74EAQ34674831-A879B541-4E03-4DDB-B5F3-0330C21995C5Q35055154-E7652F08-8ED3-4F23-8419-D0DFBFE8B634Q35100779-B326569B-CB6C-4CE9-BF74-155A4625D43DQ35812875-A89B26F3-308F-47D3-92F5-249D4BD14046Q35874111-C7E3181E-158C-4021-A85E-23BA4D8E1C84Q35947894-C3491CA0-A116-43A3-AD10-889416E593B8Q36276014-FF36A0EB-FA06-4BA1-93F3-059BB27F6C5EQ36393396-BDB804A4-402C-46FA-9E33-56415B27B155Q36452600-B90FA778-1EAC-476A-B98C-8622656E042FQ36543297-99716939-86F3-4553-AD49-3242C413D8DBQ36837134-2B8EE20C-CE2C-4C2E-822F-7CB56CC0A90DQ36967974-53C83C42-769A-4794-9AF4-76B9112CD632Q36968260-D3243A66-0FFD-4355-B126-6828071E0A60Q37017265-A1EFED4B-1C63-47B0-89FE-1BB788C096C8Q37071008-60FAA573-A8D4-4B45-A033-A5098013E346Q37434529-5C44779C-495E-4106-B52A-2C04A993B98EQ37461377-09E35E1C-E1B8-4D77-94BF-A79A4E58C973Q37655007-8611A26C-D4DA-4362-A6E0-DD7CE0C7D592Q37678409-73CBEDF1-1DB4-4901-BC0D-CA5D4431FDE2Q37706610-9CEB1BA8-2AEC-4616-BC42-DDE33C468523Q37718978-221DBCED-B504-4E03-AA8A-42BC2D397C59Q37750489-C02BDA4F-C158-4D34-85DF-6CBF165A661CQ37812128-5D698CFE-2BA8-458C-A261-90C3A0278F32
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The virosome concept for influenza vaccines
@ast
The virosome concept for influenza vaccines
@en
The virosome concept for influenza vaccines
@nl
type
label
The virosome concept for influenza vaccines
@ast
The virosome concept for influenza vaccines
@en
The virosome concept for influenza vaccines
@nl
prefLabel
The virosome concept for influenza vaccines
@ast
The virosome concept for influenza vaccines
@en
The virosome concept for influenza vaccines
@nl
P2093
P50
P1433
P1476
The virosome concept for influenza vaccines
@en
P2093
Abraham M Palache
Abraham M. Palache
Jeroen Medema
Laura Bungener
Toon Stegmann
P356
10.1016/J.VACCINE.2005.04.026
P407
P577
2005-07-01T00:00:00Z
2005-07-08T00:00:00Z